 To date, landiolol has the shortest plasma half-time and the highest cardio-selectivity among β-blockers in clinical use.The selectivity of landiolol for β1-receptor blockade is 255 times higher than for β2-receptor blockade.In comparison Metoprolol, has a much less cardioselectivity (landiolol is 100 times more cardioselective than metoprolol, and 8 times more cardioselectove than esmolol), and sixty times longer half-life (3–4 hours comparing to 3–4 minutes in case of landiolol).